Arcus Biosciences Inc (NYSE: RCUS) on Friday, soared 3.07% from the previous trading day, before settling in for the closing price of $10.74. Within the past 52 weeks, RCUS’s price has moved between $10.63 and $20.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 186.11% over the past five years. The company achieved an average annual earnings per share of 17.81%. With a float of $59.66 million, this company’s outstanding shares have now reached $91.50 million.
Let’s look at the performance matrix of the company that is accounted for 577 employees. In terms of profitability, gross margin is 96.2%, operating margin of -120.91%, and the pretax margin is -102.28%.
Arcus Biosciences Inc (RCUS) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcus Biosciences Inc is 43.28%, while institutional ownership is 49.57%. The most recent insider transaction that took place on Feb 18 ’25, was worth 14,999,996. In this transaction 10% Owner of this company bought 1,363,636 shares at a rate of $11.00, taking the stock ownership to the 31,424,760 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Chief Financial Officer sold 3,594 for $15.00, making the entire transaction worth $53,910. This insider now owns 60,138 shares in total.
Arcus Biosciences Inc (RCUS) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.81% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.18% during the next five years compared to -23.70% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
Arcus Biosciences Inc (RCUS) is currently performing well based on its current performance indicators. A quick ratio of 5.23 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -1.25 in the next quarter and is forecasted to reach -4.61 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Arcus Biosciences Inc (NYSE: RCUS) saw its 5-day average volume 2.51 million, a positive change from its year-to-date volume of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 11.26%. Additionally, its Average True Range was 0.77.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 5.27%, which indicates a significant decrease from 13.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 86.76% in the past 14 days, which was higher than the 59.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.18, while its 200-day Moving Average is $15.60. Nevertheless, the first resistance level for the watch stands at $11.55 in the near term. At $12.03, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.40. If the price goes on to break the first support level at $10.70, it is likely to go to the next support level at $10.33. Assuming the price breaks the second support level, the third support level stands at $9.85.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
Market capitalization of the company is 1.16 billion based on 91,512K outstanding shares. Right now, sales total 117,000 K and income totals -307,000 K. The company made 48,000 K in profit during its latest quarter, and -92,000 K in sales during its previous quarter.
